Topic : Medications

Other Topics :

ASH 2016: A half-step may help on the road to TFR

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – In previous articles we’ve discussed the most recent information about treatment-free remission (TFR), in which people with a deep molecular response to treatment are able
Continue Reading →

ASH 2016: Stop trials – what if I lose my response?

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 2 Part 1 of this article summarized the results of recent Stop trials, which found that about 50% of people who try stopping their CML medication can remain in TFR (treatment
Continue Reading →

ASH 2016: Updated results from recent Stop trials

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 Part 1 Part 2 Perhaps the hottest topic in CML research is whether people can stop taking their medication if they respond well to treatment for an extended period – what has been
Continue Reading →

ASH 2016: “Room for improvement” in CML monitoring, treatment

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – A new Canadian study has examined how often people with CML are tested to determine their response to medication (Hillis and colleagues. ASH 2016; abstract 3079). Informat
Continue Reading →

ASH 2016: Stem-cell transplantation: updated results

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – With the advent of tyrosine kinase inhibitor (TKI) therapies, stem-cell transplantation (SCT) is less commonly used to treat CML. While it does offer the potential of curi
Continue Reading →

ASH 2016: New treatment trials at ASH 2016

Highlights from the American Society of Hematology (ASH) annual meeting, San Diego CA, December 3-6, 2016 – The annual meeting of the American Society of Hematology is the largest medical congress of the year, and featured the results of several new trials on chronic myelogenous
Continue Reading →

Drug costs: the hidden impact on adherence

Recent studies have indicated that about 1 in 5 people with CML have problems with adherence, i.e. taking their medication as directed by their doctor (Okumura and colleagues. Pharm Pract 2015;13:559; Trivedi and colleagues. J Manag Care Spec Pharm 2014;20:1006-1015). There are many r
Continue Reading →

ASCO 2016: More trial results on stopping treatment

In recent years, the goal of treating CML has fundamentally shifted from controlling the disease process with a TKI medication (e.g. Gleevec, Tasigna, Sprycel, Bosulif) to something more ambitious: a suppression of CML that is so profound that treatment will no longer be needed. Preli
Continue Reading →